Hompesch, Marcus

Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes

DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 293

Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes

Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 170

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

de la Peña, A., Riddle, M., Morrow, L. A., Jiang, H. H., Linnebjerg, H., Scott, A., Win, K. M., Hompesch, M., Mace, K. F., Jacobson, J. G., et al. (2011) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 125

Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals

Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism

Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 88

Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study

Pratley, R. E., Kang, J., Trautmann, M. E., Hompesch, M., Han, O., Stewart, J., Sorli, C. H., Jacob, S., & Yoon, K. (2019) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 49

HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial

Abdelmalek, M., Choi, J., Kim, Y., Seo, K., Hompesch, M., & Baek, S. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 30

Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase

Hompesch, M., Muchmore, D. B., Morrow, L., Ludington, E., & Vaughn, D. E. (2012) · Diabetes Technology & Therapeutics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 25

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

Hompesch, M., Morrow, L., Watkins, E., Roepstorff, C., Thomsen, H. F., & Haahr, H. (2014) · Clinical Therapeutics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 20